Objective: High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy with a 5-year survival rate of 40% or less when diagnosed with late-stage disease. There is a dramatic benefit to early diagnosis of HGSOC with a 5-year survival rate of nearly 90% for stage I disease. Unfortunately, the majority of HGSOC is diagnosed as late-stage disease, and there are no reliable early screening or diagnostic tests. The objective of this study is to identify tumor-specific aberrant DNA methylation alterations detectable in circulation in order to develop a biomarker to detect early-stage HGSOC.
Get Full Access: https://www.gynecologiconcology-online.net/article/S0090-8258(20)31176-8/abstract
